argenx SE (ARGX)
| Market Cap | 22.48B |
| Revenue (ttm) | 10.74M |
| Net Income (ttm) | -436.15M |
| Shares Out | 59.08M |
| EPS (ttm) | -7.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,370 |
| Open | 380.18 |
| Previous Close | 380.28 |
| Day's Range | 376.86 - 382.65 |
| 52-Week Range | 327.73 - 550.76 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 506.16 (+33.05%) |
| Earnings Date | Oct 31, 2023 |
About ARGX
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is... [Read more]
Financial Performance
In 2022, argenx SE's revenue was 10.03 million, a decrease of -97.98% compared to the previous year's 497.28 million. Losses were -709.59 million, 73.8% more than in 2021.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $506.16, which is an increase of 33.05% from the latest price.
News
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...
ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...
This biotech stock is down 25% on Wednesday: find out why
Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.
Argenx stock dives by a third after late-stage trial didn't meet goals
Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigi...
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, ...
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Regulated information – Inside information
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enab...
argenx to Present at Upcoming Investor Conferences
November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia...
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
$329 million in third quarter global net product sales On track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host c...
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Argenx's 28% Surge & Promising Product Propel Investor Confidence
The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condition that affects muscle ...
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
Amsterdam, The Netherlands — Sep. 2 1 , 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
Amsterdam, The Netherlands— September 15 , 2023 —argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
$269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART® Hytrulo now available in the U.S. with first vials shipped in July Global VYVGART expansion continued...
argenx announces closing of global offering
Regulated information – Inside i nformation July 24, 2023, 4 : 30 PM ET July 24, 2023, 10 : 30 PM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company comm...
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
argenx announces full exercise of underwriters' option to purchase additional ADSs
Regulated information — Inside information July 19, 2023 , 11:58 PM C ET July 19, 2023 , 5:58 PM ET Amsterdam , the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company commi...
argenx raises $1.1 billion in gross proceeds in a global offering
Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company comm...
argenx announces launch of proposed global offering
Regulated information — Inside information argenx announces launch of proposed global offering July 17 , 2023 Amsterdam , the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology com...
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role i...
China's NMPA approves Argenx's and Zai Lab's BLA for muscle-weakening disease treatment
China's National Medical Products Administration (NMPA) has approved Zai Lab Limited's and Argenx SE's Biologics License Application (BLA) for VYVGART, a treatment for generalised myasthenia gravis (g...
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Amsterdam, the Netherlands— June 30, 2023 -- argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (N...
US FDA approves Argenx's therapy for muscle-weakening disease
The U.S. Food and Drug Administration has approved Argenx SE's under-the-skin injection for the treatment of a muscle-weakening genetic disease called generalized myasthenia gravis, the company said o...